A5033442682- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Atrial Fibrillation Management and Outcomes
- Coronary Interventions and Diagnostics
- Cardiac Imaging and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Lipoproteins and Cardiovascular Health
- Diabetes Treatment and Management
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac Arrhythmias and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Inflammasome and immune disorders
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Disease and Adiposity
- Mechanical Circulatory Support Devices
- Cardiac Valve Diseases and Treatments
- Cardiac Structural Anomalies and Repair
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Health and Mental Health
- Hormonal Regulation and Hypertension
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Advanced MRI Techniques and Applications
- Cardiac pacing and defibrillation studies
- Cardiac Ischemia and Reperfusion
Maria Cecilia Hospital
2022-2025
Sapienza University of Rome
2024-2025
Università Cattolica del Sacro Cuore
2018-2025
Florida College
2020-2024
University of Florida
2020-2024
St. Antonius Ziekenhuis
2024
Agostino Gemelli University Polyclinic
2017-2023
Istituti di Ricovero e Cura a Carattere Scientifico
1993-2023
University of the Sacred Heart
2022
Pontifícia Universidade Católica de São Paulo
2022
Antiplatelet therapy is key to reducing local thrombotic complications and systemic ischaemic events among patients undergoing percutaneous coronary interventions (PCI), but it inevitably associated with increased bleeding. The continuous refinement in stent technologies, together the high incidence of recurrences after PCI understanding prognostic implications bleeding, have led a substantial evolution antiplatelet treatment regimens over past decades. Numerous investigations been conducted...
Abstract Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for reduction ischaemic events in patients with acute coronary syndrome (ACS). However, this comes at expense increased bleeding. A guided selection inhibiting therapy has potential to overcome limitation. We aimed evaluating comparative safety and efficacy vs. routine ACS. Methods results performed a network meta-analysis randomized controlled trials (RCTs) comparing different oral currently recommended...
At one end of the coronary artery disease (CAD) spectrum, there are patients with multiple recurrent acute syndromes (rACS), and at other those long-standing clinical stability. Predicting natural history these is challenging because unstable plaques often heal without resulting in ACS.To assess vivo atherosclerotic phenotype as well prevalence characteristics healed by optical coherence tomography (OCT) imaging extremes CAD spectrum.This an observational, single-center cohort study...
To evaluate the trend of prescription four foundational therapies, and their impact on 30-day urgent re-admissions all-cause death in patients with heart failure reduced ejection fraction (HFrEF) following an acute decompensation event. Retrospective. One tertiary referral centre. 999 consecutively admitted a primary diagnosis HFrEF between January 2020 June 2023 were identified through validated, high-performance technology infrastructure based artificial intelligence. The entire cohort was...
Background Guidelines recommend using multiple drugs in patients with heart failure (HF) reduced ejection fraction, but there is a paucity of real-world data on the simultaneous initiation 4 pharmacological pillars at discharge after decompensation event. Methods and Results A retrospective mart, including diagnosed HF, was implemented. Consecutively admitted HF fraction were selected through an automated approach categorized according to number/type treatments prescribed discharge. The...